| From: Moonray | 12/30/2020 9:59:12 AM | | | | | | Dialysis clinics provide new path for delivery
of stockpiled COVID-19 antibody drugs in U.S.
Dialysis centers in the United States are rolling out COVID-19
antibody treatments this week, a new path for delivery of Eli Lilly
and Regeneron drugs approved for emergency use but facing
skepticism and logistical problems in some hospitals.
Supplies of the drugs are piling up as hospitals grapple with
overflowing wards and mass vaccinations. Kidney dialysis
patients are among those most at risk from COVID-19,
which is especially deadly among people with chronic
illnesses.
More at: nationalpost.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 1/12/2021 12:13:25 PM | | | | | | Eli Lilly CEO says Covid variant from
South Africa may ‘evade’ its antibody drug
Kevin Stankiewicz
Eli Lilly CEO Dave Ricks told CNBC the company is not sure whether its Covid-19 antibody drugs will be effective against a coronavirus strain initially found in South Africa. However, he expressed confidence that the treatment would work on the variant found in the U.K.
“The South African variant ... is the one of concern. It has more dramatic mutations to that spike protein, which is the target” of these antibody drugs, Ricks said on “Squawk Box.” “Theoretically, it could evade our medicines.”
He said the company wants to work with the Food and Drug Administration on a plan to adapt antibody therapies to virus variants, including the one first discovered in South Africa.
“We actually have a large library of these antibodies now that are sitting pre-clinically,” said Ricks. “We could think about a very expedited path to study them in maybe a month or two, and then authorize their use. That would seem to be a smart thing to do as this virus mutates.”
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 1/21/2021 9:46:21 AM | | | | | | Monoclonal antibody treatment by Eli Lilly found
to cut risk of serious COVID-19, drugmaker reports
Karen Weintraub, USA TODAY, Jan 21, 2021
A drug developed by Eli Lilly and Company dramatically
reduced the risk of developing symptomatic COVID-19
among nursing home residents, the company found.
Of 299 residents, half of whom received a placebo, those
randomized to receive the drug bamlanivimab had up to
an 80% lower risk of contracting COVID-19, according to
a study that has not yet been published.
More at: usatoday.com
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 1/27/2021 10:24:55 AM | | | | | | Eli Lilly teams up with pharma rival GSK and
partner Vir for COVID-19 antibody cocktail test
COVID-19 has been a real leveler in competitor terms;
once warring Big Pharmas have joined forces for the
greater good on vaccines, both in R&D and more recently
on production, and now on treatments.
Today, Lilly penned a deal with GlaxoSmithKline and biotech
partner Vir to wed the former’s emergency-cleared COVID-19
antibody bamlanivimab 700 mg with GSK/Vir’s experimental
therapy VIR-7831 (aka GSK4182136) 500 mg.
The hope is that in the so-called Blaze-4 trial, which has been
expanded to accommodate this combo, will see the two
neutralizing antibodies that bind to different epitopes of the
SARS-CoV-2 spike protein create better potency and make
the virus less likely to evade, especially with new variants.
More at: Eli Lilly teams up with pharma rival GSK
and partner Vir for COVID-19 antibody cocktail test
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 1/29/2021 10:51:08 AM | | | | | | Eli Lilly profit benefits from successful
launch of Covid antibody treatment
Melodie Warner
Eli Lilly's fourth-quarter profit beat Wall Street estimates, thanks
in part to strong demand for its diabetes and cancer drugs and
sales of its Covid-19 antibody treatment, Reuters reported.
Eli Lilly’s new COVID-19 treatment helped the drugmaker’s
fourth-quarter profit surge even though U.S. regulators approved
its use late in the quarter.
The antibody treatment bamlanivimab brought in $850 million
in U.S. sales for Lilly after the Food and Drug Administration
authorized emergency use in November for patients with
mild-to-moderate COVID-19.
The company's overall sales rose 21.7% to $7.44 billion.
Excluding items, Eli Lilly earned $2.75 per share, beating
estimates of $2.35 per share.
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Moonray | 2/26/2021 11:13:48 AM | | | | | | U.S. buys 100,000 courses of Eli Lilly’s latest antibody treatment
Sara Salinas
The United States has agreed to purchase 100,000 treatment courses
of Eli Lilly’s recently approved antibody treatment for Covid-19.
The agreement comes at an initial purchase price of $210 million and
includes an option to buy additional supply as needed, up to 1.2 million
total treatment courses.
The therapeutic from Eli Lilly combines two monoclonal antibodies,
bamlanivimab and etesevimab, administered through an IV infusion
to treat high-risk Covid patients who are displaying symptoms but
have not yet developed severe disease.
It received an emergency use authorization from the Food and Drug
Administration earlier this month.
o~~~ O |
| | Eli Lilly | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
